Nasdaq · CIK 0001000694
NVAX NOVAVAX INC
Insider trading from SEC Form 4. Last filing Jun 23, 2026. Close $12.75 on Oct 9, 2026, +105% from the 52-week low and 0% from the high.
NOVAVAX INC (NVAX) has 57 SEC Form 4 filings on file from 14 insiders, the latest filed on Jun 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at NVAX. The newest: Rachel K. King (director) sold $37k of stock on Dec 13, 2024, filed Jan 2, 2025, scored 26 (weak).
NVAX closed at $12.75 on Oct 9, 2026, 105% above its 52-week low and at a 52-week high.
6 Form 144 notices of planned sales are on file, the latest filed May 27, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NOVAVAX INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | Rachel K. King director sell | $37k 4,150 shares | -22% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 27, 2026 | Ruxandra Draghia Akli Former Officer | 21,383 0.01% of outstanding | $235k | May 27, 2026 | $296k |
| May 7, 2026 | Ruxandra Draghia Akli Former Officer | 30,000 0.02% of outstanding | $296k | May 7, 2026 | none |
| May 19, 2025 | YOUNG JAMES F Former Director | 10,000 0.01% of outstanding | $76k | May 19, 2025 | $24k |
| Apr 14, 2025 | YOUNG JAMES F Former Director | 4,000 0.00% of outstanding | $24k | Apr 14, 2025 | none |
| Dec 26, 2024 | YOUNG JAMES F Director | 10,000 0.01% of outstanding | $85k | Dec 24, 2024 | none |
| Dec 13, 2024 | Rachel K. King Board Member | 4,150 0.00% of outstanding | $37k | Dec 13, 2024 | none |
Transactions
The newest 50 of 155 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2026 | David M Mott director | MOption exercise Common Stock | +18,880 | - | - | 79,770 | Jun 23, 2026 |
| Jun 20, 2026 | Richard J Rodgers director | MOption exercise Common Stock | +18,880 | - | - | 47,370 | Jun 23, 2026 |
| Jun 20, 2026 | Margaret G McGlynn director | MOption exercise Common Stock | +18,880 | - | - | 44,468 | Jun 23, 2026 |
| Jun 20, 2026 | Richard Douglas director | MOption exercise Common Stock | +18,880 | - | - | 73,220 | Jun 23, 2026 |
| Jun 20, 2026 | Gregg H Alton director | MOption exercise Common Stock | +18,880 | - | - | 47,685 | Jun 23, 2026 |
| Jun 18, 2026 | Charles W. Newton director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | John W. Shiver director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 20, 2026 | Rachel K. King director | MOption exercise Common Stock | +18,880 | - | - | 44,070 | Jun 23, 2026 |
| Jun 18, 2026 | Rachel K. King director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | Margaret G McGlynn director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | David M Mott director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | Gregg H Alton director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | John W. Shiver director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | Richard J Rodgers director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | Charles W. Newton director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | Richard Douglas director | AGrant or award Stock Option (Right to Buy)derivative | +21,270 | $0.00 | $0 | 21,270 | Jun 23, 2026 |
| Jun 18, 2026 | Richard Douglas director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | Rachel K. King director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | David M Mott director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | Margaret G McGlynn director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | Richard J Rodgers director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 18, 2026 | Gregg H Alton director | AGrant or award Restricted Stock Unitsderivative | +14,180 | $0.00 | $0 | 14,180 | Jun 23, 2026 |
| Jun 20, 2026 | Margaret G McGlynn director | MOption exercise Restricted Stock Unitsderivative | -18,880 | $0.00 | $0 | 0 | Jun 23, 2026 |
| Jun 20, 2026 | Richard Douglas director | MOption exercise Restricted Stock Unitsderivative | -18,880 | $0.00 | $0 | 0 | Jun 23, 2026 |
| Jun 20, 2026 | Richard J Rodgers director | MOption exercise Restricted Stock Unitsderivative | -18,880 | $0.00 | $0 | 0 | Jun 23, 2026 |
| Jun 20, 2026 | David M Mott director | MOption exercise Restricted Stock Unitsderivative | -18,880 | $0.00 | $0 | 0 | Jun 23, 2026 |
| Jun 20, 2026 | Gregg H Alton director | MOption exercise Restricted Stock Unitsderivative | -18,880 | $0.00 | $0 | 0 | Jun 23, 2026 |
| Jun 20, 2026 | Rachel K. King director | MOption exercise Restricted Stock Unitsderivative | -18,880 | $0.00 | $0 | 0 | Jun 23, 2026 |
| Apr 25, 2026 | Charles W. Newton director | MOption exercise Common Stock | +9,520 | $0.00 | $0 | 9,520 | Apr 28, 2026 |
| Apr 25, 2026 | Charles W. Newton director | MOption exercise Restricted Stock Unitsderivative | -9,520 | $0.00 | $0 | 19,040 | Apr 28, 2026 |
| Apr 14, 2026 | Robert Edward Walker EVP, R&D | AGrant or award Stock Option (Right to Buy)derivative | +99,500 | $0.00 | $0 | 99,500 | Apr 16, 2026 |
| Apr 14, 2026 | Robert Edward Walker EVP, R&D | AGrant or award Restricted Stock Unitsderivative | +66,000 | $0.00 | $0 | 6,600 | Apr 16, 2026 |
| Mar 10, 2026 | John W. Shiver director | MOption exercise Common Stock | +7,947 | $0.00 | $0 | 7,947 | Mar 12, 2026 |
| Mar 10, 2026 | John W. Shiver director | MOption exercise Restricted Stock Unitsderivative | -7,947 | $0.00 | $0 | 15,893 | Mar 12, 2026 |
| Mar 7, 2026 | James Patrick Kelly EVP, CFO and Treasurer | MOption exercise Common Stock | +12,223 | $0.00 | $0 | 136,503 | Mar 9, 2026 |
| Mar 2, 2026 | Elaine O'Hara EVP, Chief Strategy Officer | AGrant or award 2026 Non-statutory Stock Option NQderivative | +177,500 | $0.00 | $0 | 177,500 | Mar 9, 2026 |
| Mar 2, 2026 | James Patrick Kelly EVP, CFO and Treasurer | AGrant or award Non-statutory Stock Option NQderivative | +194,000 | $0.00 | $0 | 194,000 | Mar 9, 2026 |
| Mar 2, 2026 | John C Jacobs President and CEO | AGrant or award Non-Statutory Stock Option NQderivative | +551,500 | $0.00 | $0 | 551,500 | Mar 9, 2026 |
| Mar 2, 2026 | Ruxandra Draghia-Akli EVP, Research & Development | AGrant or award Non-Statutory Stock Option NQderivative | +139,500 | $0.00 | $0 | 139,500 | Mar 9, 2026 |
| Mar 2, 2026 | Mark J Casey EVP, Chief Legal Officer | AGrant or award Non-Statutory Stock Option NQderivative | +152,000 | $0.00 | $0 | 152,000 | Mar 9, 2026 |
| Mar 7, 2026 | James Patrick Kelly EVP, CFO and Treasurer | FTax withholding Common Stock | -5,904 | $9.98 | $59k | 130,599 | Mar 9, 2026 |
| Mar 7, 2026 | James Patrick Kelly EVP, CFO and Treasurer | MOption exercise Restricted Stock Unitsderivative | -12,223 | $0.00 | $0 | 0 | Mar 9, 2026 |
| Mar 3, 2026 | Mark J Casey EVP, Chief Legal Officer | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 101,445 | Mar 5, 2026 |
| Mar 3, 2026 | Ruxandra Draghia-Akli EVP, Research & Development | MOption exercise Common Stock | +26,667 | $0.00 | $0 | 34,876 | Mar 5, 2026 |
| Mar 3, 2026 | John C Jacobs President and CEO | MOption exercise Common Stock | +150,167 | $0.00 | $0 | 264,130 | Mar 5, 2026 |
| Mar 3, 2026 | James Patrick Kelly EVP, CFO and Treasurer | MOption exercise Common Stock | +43,167 | $0.00 | $0 | 145,130 | Mar 5, 2026 |
| Mar 3, 2026 | Elaine O'Hara EVP, Chief Strategy Officer | MOption exercise Common Stock | +56,334 | $0.00 | $0 | 157,071 | Mar 5, 2026 |
| Mar 3, 2026 | Mark J Casey EVP, Chief Legal Officer | FTax withholding Common Stock | -11,378 | $9.49 | $108k | 90,067 | Mar 5, 2026 |
| Mar 3, 2026 | Ruxandra Draghia-Akli EVP, Research & Development | FTax withholding Common Stock | -11,313 | $9.49 | $107k | 23,563 | Mar 5, 2026 |
| Mar 3, 2026 | John C Jacobs President and CEO | FTax withholding Common Stock | -69,288 | $9.49 | $658k | 225,680 | Mar 5, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Gregg H Altondirector
- Mark J CaseyEVP, Chief Legal Officer
- Richard Douglasdirector
- Ruxandra Draghia-AkliEVP, Research & Development
- John C JacobsPresident and CEO
- James Patrick KellyEVP, CFO and Treasurer
- Rachel K. Kingdirector
- Margaret G McGlynndirector
- David M Mottdirector
- Charles W. Newtondirector, cfo, officer
- Elaine O'HaraEVP, Chief Strategy Officer
- Richard J Rodgersdirector
- John W. Shiverdirector
- Robert Edward WalkerEVP, R&D
Questions about NVAX
Answered from the filings on this page, as of the latest one.
Are insiders buying NVAX?
No. In the last 90 days no insider at NOVAVAX INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NVAX on the open market?
Rachel K. King (director) sold $37k of NVAX on Dec 13, 2024 and filed the Form 4 on Jan 2, 2025. InsiderTell scored 26 (weak).
How many insiders file Form 4 at NOVAVAX INC?
14 people have filed a Form 4 at NOVAVAX INC, among them Gregg H Alton (director), Mark J Casey (EVP, Chief Legal Officer), Richard Douglas (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.